Related Experiment Video
Updated: May 4, 2026

Rose Bengal-Mediated Photodynamic Therapy to Inhibit Candida albicans
Published on: March 24, 2022
Interaction of terbinafine (anti-fungal agent) with perhexiline: a case report
Abdul Rauf Sheikh1, Ian Westley2, Benedetta Sallustio3
1The Discipline of Medicine, The Queen Elizabeth Hospital, The University of Adelaide, Adelaide, South Australia; Cardiology Unit, The Queen Elizabeth Hospital, Central Adelaide Local Health Network.
Abstract:
Perhexiline is a unique anti-anginal agent that is frequently used in the treatment of chronic refractory angina. Its utility has been limited because of its complex pharmacokinetics that were only appreciated following the development of a therapeutic perhexiline assay. Perhexiline is cleared primarily via formation of mono-hydroxy metabolites (OH-perhexiline) by cytochrome P450 2D6 (CYP2D6). Drugs that are inhibitors of CYP2D6 may therefore inhibit perhexiline metabolism, increase plasma perhexiline concentration and may consequently increase the risk of toxicity. We report a case of a rise in perhexiline plasma concentration to a toxic level following the introduction of terbinafine hydrochloride; a moderate CYP2D6 inhibiting drug.
Insights
The anti-anginal drug perhexiline can reach toxic levels when taken with terbinafine, a CYP2D6 inhibitor. This interaction highlights the importance of monitoring perhexiline levels during co-administration with CYP2D6 inhibiting medications.
Area of Science:
- Pharmacology
- Drug Metabolism
- Clinical Toxicology
Background:
- Perhexiline is an anti-anginal medication used for chronic refractory angina.
- Its use is limited by complex pharmacokinetics, particularly its metabolism.
- Perhexiline is primarily metabolized by cytochrome P450 2D6 (CYP2D6).
Observation:
- Cytochrome P450 2D6 (CYP2D6) inhibitors can impede perhexiline metabolism.
- This inhibition can lead to increased plasma perhexiline concentrations and potential toxicity.
- A case study revealed elevated perhexiline levels after initiating terbinafine hydrochloride.
Findings:
- Terbinafine hydrochloride is identified as a moderate inhibitor of CYP2D6.
- The introduction of terbinafine led to a significant rise in a patient's perhexiline plasma concentration.
- Perhexiline levels reached a toxic threshold due to this drug interaction.
Implications:
- Clinicians should exercise caution when prescribing CYP2D6 inhibitors with perhexiline.
- Therapeutic drug monitoring of perhexiline is crucial when co-administering with CYP2D6 inhibitors.
- Understanding drug-drug interactions involving CYP2D6 is vital for patient safety and effective angina treatment.
More Related Videos
Related Concept Videos
Antifungal Agents
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Anthelminthic Agents
Pharmacokinetics: Drug–Drug Interactions

